Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL) -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (161)	11/17/2003 7:29:53 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 566

>> but these reports do provide interesting metrics to think about and some insights I most likely miss << I get TONS of new stuff from them. Agree completely. And, as always, thanks! Haircuts..... nobody valued the rhinitis project at better than a nickel, pre-MPM Capital. I agree with you..... the HCV market size (which is certainly better than $3 billion) demands a bit of premium. But it's an upgrade at a strange time and with strange rationale, given peer comparison. Where were they when the market cap was about the price of a beer? Wasn't that long ago.